These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11983251)

  • 1. HIV vaccine strategies.
    Nabel GJ
    Vaccine; 2002 May; 20(15):1945-7. PubMed ID: 11983251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation.
    Wang B; Boyer J; Srikantan V; Ugen K; Gilbert L; Phan C; Dang K; Merva M; Agadjanyan MG; Newman M
    Virology; 1995 Aug; 211(1):102-12. PubMed ID: 7645204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalent recognition of HIV proteins, Env, Gag and Pol, by CD4+ and CD8+ cytotoxic T-lymphocytes.
    Kundu SK; Merigan TC
    AIDS; 1992 Jul; 6(7):643-9. PubMed ID: 1354446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
    Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
    Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
    Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
    AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
    Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
    J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.
    zur Megede J; Otten GR; Doe B; Liu H; Leung L; Ulmer JB; Donnelly JJ; Barnett SW
    J Virol; 2003 Jun; 77(11):6197-207. PubMed ID: 12743276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL.
    McKinney DM; Skvoretz R; Livingston BD; Wilson CC; Anders M; Chesnut RW; Sette A; Essex M; Novitsky V; Newman MJ
    J Immunol; 2004 Aug; 173(3):1941-50. PubMed ID: 15265928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies.
    Gorse GJ; Patel GB; Mandava MD; Belshe RB
    Vaccine; 1999 Dec; 18(9-10):835-49. PubMed ID: 10580197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model.
    Earl PL; Wyatt LS; Montefiori DC; Bilska M; Woodward R; Markham PD; Malley JD; Vogel TU; Allen TM; Watkins DI; Miller N; Moss B
    Virology; 2002 Mar; 294(2):270-81. PubMed ID: 12009868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
    Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
    J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins.
    Leung NJ; Aldovini A; Young R; Jarvis MA; Smith JM; Meyer D; Anderson DE; Carlos MP; Gardner MB; Torres JV
    Virology; 2000 Mar; 268(1):94-103. PubMed ID: 10683331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
    Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
    Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of HIV-1 antigens for rapid intracellular degradation enhances cytotoxic T lymphocyte (CTL) recognition and the induction of de novo CTL responses in vivo after immunization.
    Tobery TW; Siliciano RF
    J Exp Med; 1997 Mar; 185(5):909-20. PubMed ID: 9120397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-dependent inhibition of Gag cellular immunity by Env in SIV/HIV DNA vaccinated macaques.
    Valentin A; Li J; Rosati M; Kulkarni V; Patel V; Jalah R; Alicea C; Reed S; Sardesai N; Berkower I; Pavlakis GN; Felber BK
    Hum Vaccin Immunother; 2015; 11(8):2005-11. PubMed ID: 26125521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen.
    Leung L; Srivastava IK; Kan E; Legg H; Sun Y; Greer C; Montefiori DC; zur Megede J; Barnett SW
    AIDS; 2004 Apr; 18(7):991-1001. PubMed ID: 15096801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.
    Carmichael A; Jin X; Sissons P; Borysiewicz L
    J Exp Med; 1993 Feb; 177(2):249-56. PubMed ID: 8093890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.